← Back to Search

Neuromodulation

Neuromodulation for Schizophrenia

N/A
Recruiting
Research Sponsored by Scion NeuroStim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks from baseline to end of treatment
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate a new way to treat schizophrenia by stimulating the brain and using imaging to measure the effects.

Who is the study for?
This trial is for adults over 18 with schizophrenia or schizoaffective disorder, who have trouble recognizing their illness. They must speak English, be on stable medication for two months, and able to consent. Excluded are those with recent eye surgery, ear infections, substance dependence (except caffeine/nicotine), metal implants/pacemakers affecting MRI scans, pregnancy, vestibular dysfunction, severe medical conditions or thought disorders.
What is being tested?
The study tests a non-invasive brainstem modulation device's effect on illness awareness in schizophrenia patients. It involves safe brain stimulation alongside neuroimaging to track changes in the brain related to treatment response and recognition of the illness.
What are the potential side effects?
While specific side effects aren't listed here as it's investigational and non-invasive stimulation is generally considered safe; potential risks may include discomfort at the stimulation site or temporary hearing issues due to proximity to the ear.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks from baseline to end of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 weeks from baseline to end of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Illness Awareness
Secondary study objectives
Examine changes in brain network activity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Investigational Stimulation Pattern-Open LabelExperimental Treatment1 Intervention
Group II: Investigational Stimulation Pattern 2-RandomizedExperimental Treatment1 Intervention
Group III: Investigational Stimulation Pattern 1-RandomizedExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Centre for Addiction and Mental HealthOTHER
375 Previous Clinical Trials
82,853 Total Patients Enrolled
59 Trials studying Schizophrenia
4,277 Patients Enrolled for Schizophrenia
Scion NeuroStimLead Sponsor
13 Previous Clinical Trials
621 Total Patients Enrolled
1 Trials studying Schizophrenia
34 Patients Enrolled for Schizophrenia

Media Library

Non-invasive brainstem modulation device (Neuromodulation) Clinical Trial Eligibility Overview. Trial Name: NCT05580211 — N/A
Schizophrenia Research Study Groups: Investigational Stimulation Pattern 1-Randomized, Investigational Stimulation Pattern 2-Randomized, Investigational Stimulation Pattern-Open Label
Schizophrenia Clinical Trial 2023: Non-invasive brainstem modulation device Highlights & Side Effects. Trial Name: NCT05580211 — N/A
Non-invasive brainstem modulation device (Neuromodulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05580211 — N/A
~14 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top